Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Stock Report

Market Cap: US$41.1m

Cyclo Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cyclo Therapeutics's earnings have been declining at an average annual rate of -26.1%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 5.8% per year.

Key information

-26.1%

Earnings growth rate

32.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate5.8%
Return on equity-421.6%
Net Margin-1,863.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Jan 05

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Dec 12
How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Revenue & Expenses Breakdown
Beta

How Cyclo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CYTH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231-20714
30 Sep 231-19713
30 Jun 231-19713
31 Mar 231-18811
31 Dec 221-1589
30 Sep 222-1387
30 Jun 222-1386
31 Mar 221-1377
31 Dec 212-1479
30 Sep 211-1469
30 Jun 211-1248
31 Mar 211-1047
31 Dec 201-946
30 Sep 201-937
30 Jun 201-937
31 Mar 201-846
31 Dec 191-835
30 Sep 191-634
30 Jun 191-534
31 Mar 191-534
31 Dec 181-423
30 Sep 181-433
30 Jun 181-432
31 Mar 181-432
31 Dec 171-432
30 Sep 172-322
30 Jun 172-432
31 Mar 171-532
31 Dec 162-432
30 Sep 161-432
30 Jun 161-431
31 Mar 161-321
31 Dec 151-321
30 Sep 151-220
30 Jun 151-120
31 Mar 151-120
31 Dec 142-120
30 Sep 141010
30 Jun 141010
31 Mar 142010
31 Dec 132010
30 Sep 132010
30 Jun 132010
31 Mar 131010

Quality Earnings: CYTH is currently unprofitable.

Growing Profit Margin: CYTH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CYTH is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.

Accelerating Growth: Unable to compare CYTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: CYTH has a negative Return on Equity (-421.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.